Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00068549
Other study ID # GOG-9912
Secondary ID NCI-2012-02553CD
Status Completed
Phase Phase 1
First received September 10, 2003
Last updated December 23, 2014
Start date October 2003

Study information

Verified date December 2014
Source Gynecologic Oncology Group
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This phase I trial is studying the side effects and best dose of gemcitabine when given together with radiation therapy and cisplatin in treating patients with cervical cancer that has not spread beyond the pelvis. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining cisplatin with gemcitabine may make the tumor cells more sensitive to radiation therapy and may kill more tumor cells.


Description:

PRIMARY OBJECTIVES:

I. Determine the toxicity of pelvic radiotherapy and concurrent cisplatin and gemcitabine in patients with cervical carcinoma limited to the pelvis.

II. Determine the maximum tolerated dose (MTD) of gemcitabine in combination with cisplatin and pelvic radiotherapy in these patients.

SECONDARY OBJECTIVES:

I. Determine the progression-free and overall survival of patients treated with gemcitabine at the MTD in this regimen.

II. Determine the site of recurrence, local versus distant, in patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of gemcitabine.

Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression or unacceptable toxicity. Patients also undergo external whole pelvis radiotherapy once daily on days 1-5, 8-13, 15-20, 22-27, and 29-34. After completion of external beam radiotherapy, patients undergo intracavitary radiotherapy and parametrial radiotherapy. The total elapsed time for completion of all radiotherapy is not more than 8 weeks.

Cohorts of 3-6 patients receive escalating doses of gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 1 of 6 patients experiences dose-limiting toxicity.

Patients are followed every 3 months for 2 years and then every 6 months for 3 years.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date
Est. primary completion date January 2008
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Histologically confirmed primary invasive carcinoma of the uterine cervix

- Previously untreated disease

- Any cell type

- Stage IB_2, IIA, IIB, IIIA, IIIB, or IVA

- Para-aortic lymph nodes negative by radiologic evaluation or by biopsy if CT scan is suspicious for adenopathy

- No known metastases to scalene nodes or other organs outside the radiotherapy field

- Study enrollment within 8 weeks of diagnosis

- Performance status - GOG 0-2

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Bilirubin no greater than 1.5 times normal

- SGOT no greater than 3 times normal

- Creatinine less than 2.0 mg/dL

- No renal abnormalities (e.g., pelvic kidney, horseshoe kidney, or renal transplantation) that would require modification of radiotherapy fields

- No ureteral obstruction allowed unless treated with stent or nephrostomy tube

- Not pregnant

- Fertile patients must use effective contraception

- No septicemia or severe infection

- No circumstance that would preclude study completion or follow-up

- No other malignancy within the past 5 years except nonmelanoma skin cancer

- No prior cytotoxic chemotherapy

- No prior pelvic or abdominal radiotherapy

- No prior therapy for this malignancy

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Gemcitabine Hydrochloride
Given IV
Cisplatin
Given IV
Radiation:
Radiation Therapy
Undergo whole pelvis radiotherapy
Internal Radiation Therapy
Undergo brachytherapy

Locations

Country Name City State
United States Gynecologic Oncology Group Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Gynecologic Oncology Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of acute toxicity using the 21 major categories of the CTEP CTC version 2.0 Up to 30 days after completion of radiation therapy Yes
Primary Incidence of chronic toxicity using the CTC RTOG/EORTC late radiation morbidity scoring scheme Up to 5 years Yes
Primary Dose of each drug Up to 5 years No
Primary Number of cycles received Up to 5 years No
Secondary Site (local/distant) of treatment failure Up to 5 years No
Secondary Progression-free survival Up to 5 years No
Secondary Overall survival Up to 5 years No
See also
  Status Clinical Trial Phase
Completed NCT02562729 - Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Phase 2
Completed NCT00054444 - Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer Phase 1
Completed NCT00416455 - Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Phase 1/Phase 2
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Active, not recruiting NCT02140021 - Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer N/A
Completed NCT01711515 - Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer Phase 1
Terminated NCT00924066 - Ixabepilone to Treat Cervical Cancer Phase 2
Completed NCT00559377 - FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Phase 2
Completed NCT00309959 - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Active, not recruiting NCT05613283 - Primary Cervical Cancer Screening by Self-sampling HPV Test
Recruiting NCT03742869 - HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma
Withdrawn NCT03834571 - Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women Phase 2
Completed NCT01266460 - Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Completed NCT00064077 - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Phase 3
Active, not recruiting NCT02257528 - Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Phase 2
Active, not recruiting NCT02466971 - Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Phase 3
Completed NCT02164461 - Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Phase 1
Completed NCT01281852 - Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Phase 1
Active, not recruiting NCT04622670 - Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer N/A
Completed NCT02921269 - Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Phase 2